NORTH BRUNSWICK, N.J., April 7 /PRNewswire/ -- WellGen, Inc. today announced that Dr. Roderick (Roddy) Carter, M.D., M.Sc., has been appointed President and Chief Executive Officer.
Dr. Carter, 45, takes over from Robert J. Bertoldi, who was serving as interim Chief Executive Officer. Mr. Bertoldi will continue in his WellGen Board position and as President and Chief Financial Officer of Amphion Innovations plc (LSE: AMP), a significant shareholder in WellGen.
Mr. Bertoldi said, "Roddy Carter's range of experience, along with his significant achievements in medicine, research, and pharmaceutical development and commercialization, fits perfectly with WellGen as we develop medical foods using our proprietary Alignomx(TM) research model. We are very pleased to have him join the team as the company rolls out its first commercial products and continues its clinical research to develop additional products."
Since 2008, Dr. Carter has been principal at Aquila Life Sciences LLC, a consulting firm focusing on pharmaceutical development and commercialization. Before that he was Vice President of Clinical Development (2007 - 2008) at Reliant Pharmaceuticals USA, which today is a wholly owned subsidiary of GlaxoSmithKline plc. Earlier in his career, Dr. Carter was a Senior Medical Director at Pfizer, Inc. (2004-2006), where he led teams for the development and commercialization of Lipitor(TM) and Viagra(TM), among others. Prior to that, he worked as director of marketing at Merck and Co.'s Europe, Middle East, and Africa (EMEA) division, and at Merck Sharpe and Dohme (MSD) in South Africa.
Before entering the pharmaceutical industry, Dr. Carter established the Centre for the Study of Exercise, Nutrition and Muscle Science at the University of the Witwatersrand, Johannesburg, South Africa. This academic leadership position followed Dr. Carter's early professional years as a family practitioner.
|SOURCE WellGen, Inc.|
Copyright©2009 PR Newswire.
All rights reserved